Previous 10 | Next 10 |
Today, we will study why Relmada Therapeutics (RLMD) is an attractive clinical-stage biopharmaceutical pick in 2020. Company overview Relmada Therapeutics is a clinical-stage biotechnology company focused on advancing REL-1017 (d-methadone or dextromethadone) as a rapid-acting oral treat...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 144 weeks of public selections as part of this ongoing live forward-testing. In...
Relmada Therapeutics (NASDAQ: RLMD ) initiated with Buy rating and $75 (73% upside) price target at Jefferies. More news on: Relmada Therapeutics, Inc., Biogen Inc., Denali Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Relmada Therapeutics (NASDAQ: RLMD ) appoints Maged Shenouda as new Chief Financial Officer (CFO). More news on: Relmada Therapeutics, Inc., Healthcare stocks news, Read more ...
NEW YORK , Jan. 10, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Maged Shenouda has been appointed the Company's new Chief Financi...
Aerie Pharmaceuticals (NASDAQ: AERI ) initiated with Neutral rating and $27 (6% upside) price target at Bank of America. More news on: Aurinia Pharmaceuticals Inc., BeyondSpring Inc., Cerecor Inc., Healthcare stocks news, Stocks on the move, , Read more ...
NEW YORK , Dec. 20, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointments of life sciences industry veterans, Eric Schmidt , Ph....
Gainers: Mirum Pharmaceuticals (NASDAQ: MIRM ) +110% . More news on: Mirum Pharmaceuticals, Inc., Axsome Therapeutics, Inc., The Goldfield Corporation, Stocks on the move, Read more ...
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Buy rating and $60 (35% upside) price target at Guggenheim. Shares up a fraction premarket. More news on: ACADIA Pharmaceuticals Inc., Aurora Cannabis Inc., Pluristem Therapeutics Inc., Healthcare stocks news, Stocks on the move, , ...
NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference LLP announced today that it represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), a clinical stage company developing depression and central nervous system disease therapies, in the successful completion of an underwritten ...
News, Short Squeeze, Breakout and More Instantly...
Relmada Therapeutics Inc. Company Name:
RLMD Stock Symbol:
OTCMKTS Market:
Relmada Therapeutics Inc. Website:
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry PR Newswire CORAL GABLES, Fla. , June 18, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage b...
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 10, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of t...
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 3, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the cent...